


What is claimed is:

1. A compound of the formula



- 5 wherein the wavy bond (~~~~) represents the racemate, the (R)-enantiomer or the (S)-enantiomer;  
 $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  each are independently hydrogen or  $-P(O)OR^5OR^6$ ;  
 $R^5$  and  $R^6$  each are independently hydrogen or  $C_{1-4}$  alkyl;  
X is a covalent bond or  $-CR^5R^6O-$ ;  
10 or a nontoxic pharmaceutically acceptable salt or solvate thereof.
2. The compound of claim 1 which is 3-(S)-(5-Chloro-2-methoxy-phenyl)-3-fluoro-6-trifluoromethyl-1-(3-(R), 4-(S), 5-(S)-trihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-1,3-dihydro-indol-2-one or a  
15 pharmaceutically acceptable salt or solvate thereof.
3. The compound of claim 1 which is 3-(S)-(5-Chloro-2-methoxy-phenyl)-3-fluoro-6-trifluoromethyl-1-(3-(R), 4-(S), 5-(S)-trihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-2-(R)-yl)-1,3-dihydro-indol-2-one or a pharmaceutically  
20 acceptable salt or solvate thereof.
4. The compound of claim 1 which is phosphoric acid mono-{2-(R)-[3-(S)-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxo-6-trifluoromethyl-2,3-dihydro-indol-1-yl]-4-(S), 5-(S)-dihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-3-(R)-yl}  
25 ester or a pharmaceutically acceptable salt or solvate thereof.

5. A pharmaceutical composition for the treatment of disorders responsive to openers of the large conductance calcium-activated potassium channels comprising a therapeutically effective amount of a compound as defined in claim 1 in association with a pharmaceutically acceptable carrier or diluent.

5

6. A method for the treatment of disorders responsive to opening of the large conductance calcium-activated potassium channels in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound as defined in claim 1.

10

7. A method of claim 6 wherein said disorder is ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, carbon monoxide poisoning, sexual dysfunction and urinary incontinence.

15

8. The method of claim 7 wherein the disorder is stroke.

9. The method of claim 7 wherein the disorder is traumatic brain injury.